South Korea Crispr And Cas Genes Market Size & Outlook
South Korea crispr and cas genes market, 2018-2030 (US$M)
Related Markets
South Korea crispr and cas genes market highlights
- The South Korea crispr and cas genes market generated a revenue of USD 128.9 million in 2024 and is expected to reach USD 304.5 million by 2030.
- The South Korea market is expected to grow at a CAGR of 15.6% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 128.9 million |
| Market revenue in 2030 | USD 304.5 million |
| Growth rate | 15.6% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, South Korea accounted for 2.8% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,162.8 million by 2030.
Product was the largest segment with a revenue share of 87.43% in 2024. Horizon Databook has segmented the South Korea crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea’s CRISPR market is expected to be driven by strategic developments of local players. Tool Gen, Inc., one of the major players in South Korea’s CRISPR market, has undertaken multiple licensing agreements and collaborations with international companies to expand the use of its CRISPR/Cas9 technologies.
For instance, in August 2019, Tool Gen collaborated with Viva Zome Therapeutics Pty Ltd., a privately held Australian biotech company, to explore gene editing of cells for improved production of exosome s. Tool Gen employed its CRISPR/Cas9 technology to develop gene edits into selected cell types, which were further analyzed by Viva Zone.
In August 2017, Tool Gen and Monsanto Company, a U.S.-based firm, entered into a licensing agreement, under which the former’s CRISPR technology platform was utilized for development of agricultural products.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea crispr and cas genes market size, by product & service, 2018-2030 (US$M)
South Korea CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
